生物医药界竞争白热化 跨国巨头疯狂抢购“双抗药物”

电鳗快报网
17 Jun

《电鳗财经》电鳗号/文当诺华、罗氏等跨国药企挥舞着数百亿元支票在双抗领域疯狂"扫货",这场生物医药界的"军备竞赛"背后,暗藏着一个关于创新与生存的寓言。当地时间6月2日,在2025年美国临床肿瘤学会(ASCO)年会上,百时美施贵宝(BMS)宣布拟斥资最高达111亿美元与BioNTech合作,共同开发并商业化一款肿瘤药——BNT327。这是一种靶向PD-L1和VEGF-A的双特异性抗体药物,用于治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10